Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV

Clinical Infectious Diseases

Volumn 39, Issue 3, 2004, Pages 395-401

  Bassett, Ingrid V ^a,b   Freedberg, Kenneth A ^b,c   Walensky, Rochelle P ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; COMPUTER MODEL; DECISION SUPPORT SYSTEM; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL ANALYSIS; MEDICAL DECISION MAKING; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SIDE EFFECT;

ANIMALS; ANTI-HIV AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DECISION TREES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; NEEDLESTICK INJURIES; OCCUPATIONAL DISEASES; PRACTICE GUIDELINES; UNITED STATES;

EID: 3943104125     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422459     Document Type: Review

References (37)

1. Perry J. CDC releases national needlestick estimates, 2000. 2000. Available at: http://www.healthsystem.virginia.edu/internet/epinet/cdcestim. cfm. Accessed 29 January 2004.
2. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. Arch Intern Med 1993; 153:1451-8.
3. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med 1997; 102:9-15.
4. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. MMWR Morb Mortal Wkly Rep 2000; 12:24. Available at: http: //www.cdc.gov/hiv/ stats/hasr1201c.pdf.
5. Do AN, Ciesielski CA, Metler RP, Hammett TA, Li J, Fleming PL. Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States. Infect Control Hosp Epidemiol 2003; 24: 86-96.
6. Fleming PL, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV prevalence in the United States, 2000 [abstract 11]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
7. Walensky RP, Losina E, Steger-Craven KA, Freedberg KA. Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med 2002; 162:887-92.
8. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270:1197-9.
9. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-73.
10. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV setoconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Neediestick Surveillance Group. N Engl J Med 1997; 337:1485-90.
11. Gerberding JL. Clinical practice: occupational exposure to HIV in health care settings. N Engl J Med 2003; 348:826-33.
12. Parkin JM, Murphy M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000; 355:722-3.
13. Centers for Disease Control and Prevention. The HIV postexposure prophylaxis registry, 1999. Available at: http://www.cdc.gov/ncidod/ hip/blood/PEPRegistry.pdf. Accessed 29 January 2004.
14. Puro V. Post-exposure prophylaxis for HIV infection. Italian Registry of Post-Exposure Prophylaxis. Lancet 2000; 355:1556-7.
15. Puro V, De Carli G, Orchi N, et al. Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. J Biol Regul Homeost Agents 2001; 15:238-42.
16. Braitstein P, Chan K, Beardsell A, et al. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting. J Acquir Immune Defic Syndr 2002; 29:547-8.
17. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-94.
18. Centers for Disease Control and Prevention. Updated US Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001; 50:1-52.
19. Wang SA, Panlilio AL, Doi PA, White AD, Stek M Jr, Saah A. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol 2000; 21:780-5.
20. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001; 49:1153-6.
21. Bangsberg D, Goldschmidt RH. Postexposure prophylaxis for occupational exposure to HIV. JAMA 1999; 282:1623-4.
22. Rey D, Bendiane MK, Moatti JP, Wellings K, Danziger R, MacDowall W. Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview of the policies implemented in 27 European countries. AIDS Care 2000; 12:695-701.
23. Asch DA, Hershey JC. Why some health policies don't make sense at the bedside. Ann Intern Med 1995; 122:846-50.
24. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
25. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137:381-433.
26. Benn PD, Mercey DE, Brink N, Scott G, Williams IG. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 2001; 357:687-8.
27. Quirino T, Niero F, Ricci E, et al. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther 2000; 5:195-7.
28. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
29. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-8.
30. Jochimsen EM, Luo CC, Beltrami JF, Respess RA, Schable CA, Cardo DM. Investigations of possible failures of postexposure prophylaxis following occupational exposures to human immunodeficiency virus. Arch Intern Med 1999; 159:2361-3.
31. Balaguera H, Hanna, G, Heeren T, et al. Virologic response to antiretroviral therapy in chronically HIV-1-infected, antiretroviral-naive adults with baseline genotypic resistance [presentation 1747]. In: Program and abstracts of the 8th Interscience Conference of Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
32. Alexander C, Dong W, Mo T, et al. Primary antiretroviral resistance in recently infected injection drug users in drug naive individuals [abstract 218]. In: Program and abstracts of the 6th Conference of Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
33. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288:2868-79.
34. Weinstock H, Zaidi I, Woods T, Mirza S, Heneine W, Kaplan J. Prevalence of mutations associated with decreased antiretroviral drug susceptibility among recently and chronically HIV-1-infected persons in 10 US cities, 1997-99 [abstract 265]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
35. Cheingsong R, Beltrami E, Respess R, Cardo D. Prevalence of drug resistant HIV-1 in patients who are the source of occupational exposures to health care workers [abstract 496]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
36. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 1998; 279: 1984-91.
37. Yerly S, Race E, Vora S, et al. HIV drug resistance and molecular epidemiology in patients with primary HIV infection [abstract 754]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.